You are here

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience.

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 Mar 16;: Authors: Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L Abstract BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn’s disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to…

Read More

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Related Articles Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Mar 20;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M Abstract BACKGROUND: The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented. METHODS: Remission and response…

Read More

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Mar 20;: Authors: Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R Abstract BACKGROUND: Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant. AIM: To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease. METHODS: Twenty-five women from the University of Calgary…

Read More

Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn’s Disease.

Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn’s Disease. Inflamm Bowel Dis. 2017 Mar 15;: Authors: Walters TD, Faubion WA, Griffiths AM, Baldassano RN, Escher J, Ruemmele FM, Hyams JS, Lazar A, Eichner S, Huang B, Li Y, Thakkar RB Abstract BACKGROUND: Growth failure is common in children with Crohn’s disease. The effect of adalimumab (ADA), a fully human antitumor necrosis factor antagonist, on height velocity in pediatric patients with baseline (BL) linear growth impairment in the IMAgINE 1 trial is presented. METHODS: This analysis…

Read More

Intra-patient variability in adalimumab drug levels within and between cycles in Crohn’s disease.

Related Articles Intra-patient variability in adalimumab drug levels within and between cycles in Crohn’s disease. Aliment Pharmacol Ther. 2017 Feb 27;: Authors: Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP Abstract BACKGROUND: Whether therapeutic drug monitoring for adalimumab needs to be performed at the trough concentration has not been defined. AIM: To determine intra-patient adalimumab drug-level variation and to identify modulating patient and disease factors. METHODS: In this prospective observational study, adult patients with Crohn’s disease established on maintenance…

Read More

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D’Haens GR Abstract BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition…

Read More

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply.

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply. Aliment Pharmacol Ther. 2017 Mar;45(6):856-857 Authors: Radford-Smith GL, Hartnell F, Doecke JD PMID: 28211631 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28211631?dopt=Abstract

Read More

Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn’s disease – a nested case-control study.

Related Articles Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn’s disease – a nested case-control study. Aliment Pharmacol Ther. 2017 Feb 06;: Authors: Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M Abstract BACKGROUND: Data on dose de-escalation in patients with Crohn’s disease (CD) are limited. AIM: To evaluate outcomes of dose de-escalation from adalimumab (ADM) every other week (EOW) to every three weeks (ETW). METHODS: We selected patients with CD receiving maintenance therapy with ADM 40 mg ETW with…

Read More

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn’s Disease.

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017 Jan 26;: Authors: Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A Abstract BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn’s disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAgINE 2. Endpoints…

Read More
<< Go Back